Otonomy (NASDAQ:OTIC) will release its earnings data after the market closes on Monday, November 5th. Analysts expect Otonomy to post earnings of ($0.47) per share for the quarter.
Otonomy (NASDAQ:OTIC) last announced its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.06). Otonomy had a negative net margin of 6,640.16% and a negative return on equity of 56.60%. The business had revenue of $0.12 million during the quarter, compared to analyst estimates of $0.30 million. On average, analysts expect Otonomy to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Shares of OTIC stock opened at $2.48 on Friday. Otonomy has a 52-week low of $2.16 and a 52-week high of $6.45.
A number of brokerages have recently issued reports on OTIC. SunTrust Banks dropped their price objective on shares of Otonomy to $10.00 and set a “buy” rating for the company in a research note on Tuesday, August 14th. Zacks Investment Research cut shares of Otonomy from a “hold” rating to a “sell” rating in a research note on Tuesday, August 14th. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $7.58.
Otonomy, Inc, a biopharmaceutical company, engages in the development and commercialization of therapeutics for otology in the United States. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; and OTO- 313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed a Phase 1 clinical safety trial for the treatment of tinnitus.
Further Reading: What is a Call Option?
Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.